Ops, QA staff escape Genzyme's ($GENZ) job cuts

Genzyme ($GENZ) last week cut 392 filled and unfilled jobs at several locations, executing the first step in its plan to eliminate 1,000 by the end of next year. Employees got the word on Thursday.

The 1,000 represents about one-twelfth of the Cambridge, MA, biotech's workforce.

Some 185 of those cuts are in Massachusetts, but not at the troubled Allston manufacturing plant. The plant is currently operating under a consent decree with the FDA for remediation of manufacturing shortcomings. The company has been and continues to hire manufacturing and quality assurance employees, says the Boston Globe. Plans call for an additional 500 to 600 such jobs in Allston, Framingham, and elsewhere by the end of next year.

- see the article
- here's the Globe report

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.